ebomi
Colour theme
Sign in
Insider · CIK 0001376960

Aryeh Jason

CIK 0001376960 Name as filed on the most recent filing

Filed as Aryeh Jason (95)

204 transaction lines · from 95 filings · filed 2007-06-01 to 2026-06-12 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

204 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-26 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2015-11-11 S, Open-market sale Ligand Pharmaceuticals IncLGND 304,470, disposed Open Form 4 filing 0000886163-15-000116
2015-06-16 P, Open-market purchase QLT Inc/BCQLTI 999,360, acquired Open Form 4 filing 0001455244-15-000021
2015-06-04 S, Open-market sale Ligand Pharmaceuticals IncLGND 151,995, disposed Open Form 4 filing 0001209191-15-051219
2015-05-20 S, Open-market sale Ligand Pharmaceuticals IncLGND 87,650, disposed Open Form 4 filing 0000886163-15-000068
2015-05-19 S, Open-market sale Ligand Pharmaceuticals IncLGND 198,957, disposed Open Form 4 filing 0000886163-15-000068
2015-05-18 S, Open-market sale Ligand Pharmaceuticals IncLGND 520,440, disposed Open Form 4 filing 0000886163-15-000068
2014-10-09 P, Open-market purchase Ligand Pharmaceuticals IncLGND 472,890, acquired Open Form 4 filing 0000886163-14-000100
2014-02-14 S, Open-market sale Ligand Pharmaceuticals IncLGND 749,265, disposed Open Form 4 filing 0000886163-14-000028
2014-02-13 S, Open-market sale Ligand Pharmaceuticals IncLGND 518,779, disposed Open Form 4 filing 0000886163-14-000028
2014-02-12 S, Open-market sale Ligand Pharmaceuticals IncLGND 1,814,121, disposed Open Form 4 filing 0000886163-14-000028
2012-06-18 P, Open-market purchase Myrexis, Inc.MYRX 6,880, acquired Open Form 4 filing 0001181431-12-037400
2012-06-15 P, Open-market purchase Myrexis, Inc.MYRX 2,409, acquired Open Form 4 filing 0001181431-12-037045
2012-06-14 P, Open-market purchase Myrexis, Inc.MYRX 9,450, acquired Open Form 4 filing 0001181431-12-037045
2012-06-07 P, Open-market purchase Myrexis, Inc.MYRX 2,674, acquired Open Form 4 filing 0001181431-12-035832
2012-06-01 P, Open-market purchase Ligand Pharmaceuticals IncLGND 8,386, acquired Open Form 4 filing 0000886163-12-000040
2012-05-31 P, Open-market purchase Myrexis, Inc.MYRX 23,771, acquired Open Form 4 filing 0001181431-12-033828
2012-05-30 P, Open-market purchase Myrexis, Inc.MYRX 9,909, acquired Open Form 4 filing 0001181431-12-033828
2012-05-25 P, Open-market purchase Myrexis, Inc.MYRX 378, acquired Open Form 4 filing 0001181431-12-032855
2012-05-23 P, Open-market purchase Myrexis, Inc.MYRX 2,470, acquired Open Form 4 filing 0001181431-12-032855
2012-05-22 P, Open-market purchase Myrexis, Inc.MYRX 645, acquired Open Form 4 filing 0001181431-12-032050
2012-05-21 P, Open-market purchase Myrexis, Inc.MYRX 30,060, acquired Open Form 4 filing 0001181431-12-032050
2012-05-18 P, Open-market purchase Myrexis, Inc.MYRX 18,618, acquired Open Form 4 filing 0001181431-12-031431
2012-05-17 P, Open-market purchase Myrexis, Inc.MYRX 10,002, acquired Open Form 4 filing 0001181431-12-031431
2011-12-05 P, Open-market purchase Myrexis, Inc.MYRX 84,801, acquired Open Form 4 filing 0001209191-11-059760
2011-12-02 P, Open-market purchase Myrexis, Inc.MYRX 74,299, acquired Open Form 4 filing 0001209191-11-059540
2011-12-01 P, Open-market purchase Myrexis, Inc.MYRX 112,895, acquired Open Form 4 filing 0001209191-11-059540
2011-11-30 P, Open-market purchase Myrexis, Inc.MYRX 25,790, acquired Open Form 4 filing 0001209191-11-058781
2011-11-29 P, Open-market purchase Myrexis, Inc.MYRX 236,660, acquired Open Form 4 filing 0001209191-11-058781
2011-11-28 P, Open-market purchase Myrexis, Inc.MYRX 165,512, acquired Open Form 4 filing 0001209191-11-058359
2011-11-25 P, Open-market purchase Myrexis, Inc.MYRX 105,268, acquired Open Form 4 filing 0001209191-11-058359
2011-11-23 P, Open-market purchase Myrexis, Inc.MYRX 63,620, acquired Open Form 4 filing 0001209191-11-058047
2011-11-22 P, Open-market purchase Myrexis, Inc.MYRX 132,639, acquired Open Form 4 filing 0001209191-11-058047
2011-11-14 P, Open-market purchase Myrexis, Inc.MYRX 25,608, acquired Open Form 4 filing 0001209191-11-056118
2011-11-11 P, Open-market purchase Myrexis, Inc.MYRX 6,635, acquired Open Form 4 filing 0001209191-11-056118
2011-11-10 P, Open-market purchase Ligand Pharmaceuticals IncLGNDD 2 lines 21,910, acquired Open Form 4 filing 0000886163-11-000063
2011-08-10 P, Open-market purchase Ligand Pharmaceuticals IncLGND 21,140, acquired Open Form 4 filing 0000886163-11-000055
2011-05-12 P, Open-market purchase Ligand Pharmaceuticals IncLGND 18,906, acquired Open Form 4 filing 0000886163-11-000041
2011-03-16 P, Open-market purchase Ligand Pharmaceuticals IncLGND 8 lines 37,405, acquired Open Form 4 filing 0000886163-11-000033
2011-03-15 S, Open-market sale Nabi BiopharmaceuticalsNABI 28,763, disposed Open Form 4 filing 0001455244-11-000010
2011-03-15 P, Open-market purchase Ligand Pharmaceuticals IncLGND 2 lines 14,235, acquired Open Form 4 filing 0000886163-11-000033
2011-03-14 P, Open-market purchase Ligand Pharmaceuticals IncLGND 4,885, acquired Open Form 4 filing 0000886163-11-000031

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 88
  • Open-market sale 116
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Aryeh Jason, insider transactions. Retrieved 2026-08-26 from https://ebomi.com/insider/0001376960

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.